T-Cell Prolymphocytic Leukemia

This trial is testing duvelisib (an oral PI3K inhibitor) for patients with cutaneous T-cell lymphoma (CTCL) or T-cell prolymphocytic leukemia whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing stem cell transplant for patients with adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL), or T-cell prolymphocytic leukemia who have responded to prior therapy and may receive maintenance treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing Ruxolitinib for patients with T-cell prolymphocytic leukemia (T-PLL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing allogeneic stem cell transplant (from a donor) for patients with T-cell prolymphocytic leukemia (T-PLL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing a two-step haploidentical (half-matched) stem cell transplant using radiation-based reduced-intensity conditioning for patients with anaplastic large cell lymphoma (ALCL) or T-cell prolymphocytic leukemia whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to different treatment groups. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing APG-115 for patients with T-cell prolymphocytic leukemia (T-PLL) whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to different treatment groups. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing allogeneic stem cell transplant (from a donor) for patients with T-cell prolymphocytic leukemia (T-PLL) whose disease has come back or stopped responding to prior treatment as well as those who have responded to prior therapy and may receive maintenance treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to different treatment groups. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing CD30-directed CAR-T cell therapy (patient's own T cells engineered to attack CD30 on lymphoma cells) for patients with T-cell prolymphocytic leukemia (T-PLL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This is a research study collecting clinical information and/or biological samples from patients with angioimmunoblastic T-cell lymphoma (AITL) or TFH lymphomas, anaplastic large cell lymphoma (ALCL), adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL), enteropathy-associated T-cell lymphoma, extranodal NK/T-cell lymphoma, hepatosplenic T-cell lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma, peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), subcutaneous panniculitis-like T-cell lymphoma, or T-cell prolymphocytic leukemia at various stages of their disease to advance understanding of these diseases and improve future treatments. No experimental treatment is given as part of this study. This trial is available at 26 locations in the United States.

This trial is testing duvelisib (an oral PI3K inhibitor) for patients with extranodal NK/T-cell lymphoma or T-cell prolymphocytic leukemia whose disease has come back or stopped responding to prior treatment as well as those who have responded to prior therapy and may receive maintenance treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. This trial is available at 9 locations in the United States. The trial is currently recruiting patients.

This trial is testing LP-118 for patients with T-cell prolymphocytic leukemia (T-PLL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. Patients are randomly assigned to different treatment groups. This trial is available at 8 locations in the United States. The trial is currently recruiting patients.

This is a research study collecting clinical information and/or biological samples from patients with T-cell prolymphocytic leukemia (T-PLL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment to advance understanding of these diseases and improve future treatments. No experimental treatment is given as part of this study. This trial does not currently have sites in the United States.

This trial is testing CD7-targeted CAR-T cell therapy for patients with T-cell prolymphocytic leukemia (T-PLL) at various stages of their disease. Researchers want to learn whether this approach can help control the lymphoma. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing CAR-T cell therapy (genetically modified immune cells) for patients with T-cell prolymphocytic leukemia (T-PLL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. Patients are randomly assigned to different treatment groups. This trial is available at 2 locations in the United States. The trial is currently recruiting patients.